Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following i
Billionaire and celebrity entrepreneur Mark Cuban has revealed his latest move to tackle the cost of medicines in the US, agreeing a deal to make a low-cost biosimilar ver
The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they
Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn
AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in
Editor's Picks
